Delta, Kelowna, BC – April 5, 2022 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its
potcast site
release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts #630, Cannabis News and Stocks on the Move (CSE: LITE) (CSE: TRUL) (OTCQX: TCNNF) (TSX: LABS) (TSXV: KHRN)
SHARE PODCAST:
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
In today’s podcast we look at a few private and public company announcements.
Trulieve Cannabis Corp. (
CSE: TRUL
) (
OTCQX: TCNNF
), a leading and top-performing cannabis company in the United States,
announced
the launch of “4.20 for All” Non-Fungible Tokens (NFTs) Collection. The initial offerings will be available beginning on April 2, at 1pm EST which is exactly 420 hours prior to April 20 (4/20), the nationally recognized cannabis holiday. Proceeds from all Trulieve’s NFT sales will benefit a charity.
The first cannabis MSO to enter the metaverse, Trulieve’s “4.20 for All” NFT Collection will be sold on the OpenSea marketplace and can be viewed at
opensea.io/collection/trulieve-420-for-all
. Each NFT features a different hand holding a cannabis product. The campaign celebrates cannabis’ diverse community and culture, which includes all types of users and products.
This is the first in a series of 4/20 activations to be announced by Trulieve. All proceeds from the “4.20 for All” NFT Collection will be donated to the Last Prisoner Project, a non-profit organization committed to cannabis criminal justice reform and helping free the over 40,000 individuals still in prison for non-violent cannabis convictions.
“Trulieve strives to provide enhanced experiences for our customers and patients, and that now includes the metaverse, as we introduce our ‘4.20 for All’ NFT Collection,” said
Kim Rivers
, CEO of Trulieve. “This is a fun and unique way to amplify Trulieve’s steadfast belief in accessibility and to support the Last Prisoner Project.”
Highlighting some of Trulieve’s most popular products on dispensary shelves, the “4.20 for All” NFT Collection features 10 different original pieces of digital art. There will be 42 copies of each, which results in 420 total offerings in the collection. Each NFT will be initially offered at .042 Ethereum and every winner will receive a premium, personalized physical gift item.
“The campaign connects to the inclusive, diverse, and celebratory narrative that ‘4.20 for All’ inspires,” said Valda Coryat, Trulieve’s Chief Marketing Officer. “Each illustrated hand is a hand raised supporting accessibility and social justice. From a chef to a hiker … from a yogi to a musician … from an astronaut to an alien and, yes, even sasquatch. We expect fans and collectors will be excited to own these NFTs.”
Customers and patients interested in purchasing can do so without owning cryptocurrency, however they will be required to create an account with OpenSea and transfer the necessary funds to their digital wallet.
To learn more about Trulieve’s “4.20 for All” NFT Collection and how to purchase, please visit
opensea.io/collection/trulieve-420-for-all
.
MediPharm Labs Corp. (
TSX: LABS
) (
OTCQX: MEDIF
), a pharmaceutical company specialized in precision-based cannabinoids,
announced
the expansion of its adult use wellness product line with the launch of CBG and water-soluble products. As of today, these new products will be available in Ontario in both retail stores and on the OCS.ca e-commerce website. MediPharm also has purchase commitments to distribute the products to the Company’s other seven provincial distributors in the coming months.
Bryan Howcroft CEO of MediPharm commented, “Over the past 16 months, MediPharm has formulated several innovative product platforms, launched them and gained traction in the premium wellness segment of the Canadian market. The announcement today expands the Company’s portfolio to include the first naturally derived CBG products available to Canadian adult consumers and the only inhalable CBG option in Canada. With recent investments in sales and marketing functions demonstrating tangible results, our team will continue to bring differentiated wellness-focused products to market, and work to grow shelf presence as the year progresses. We also see a meaningful opportunity to introduce products such as those launched today into international markets, leveraging our unique GMP Drug Establishment and Natural Health Product manufacturing licenses, and existing global distribution partnerships.”
MediPharm Labs CBG:CBD 1:2 Advanced Formula oral solution is a high-CBG formulation, manufactured to stringent pharma-quality standards that brings customers and patients the highest quality and purity available in the market today. This full-spectrum formulated oil has a subtle cannabis flavour.
Northbound CBG:CBD The White and Appalachia vape cartridge is formulated with a terpene blend dominated by citrus zest and berry aromatic with mild herbal notes to provide balance. Vaping enables users to experience CBG with a faster onset that is easier to titrate.
MediPharm is proud to lead the industry in CBG-dominant options for patients and consumers. CBG is one of the rarer cannabinoids, and has demonstrated some potential as an antibiotic. An interdisciplinary team of McMaster researchers, which included MediPharm’s Director of Research and Development, Dr. Tait Gale, found that CBG was not only antibacterial, but also effective in mice against a resilient family of bacteria known as methicillin-resistant Staphylococcus aureus (“MRSA”). Discovering that CBG has antibacterial properties was significant given that the MRSA bacterial strain is a leading cause of infections worldwide and has become increasingly resistant to antibiotics currently on the market.[1]
MediPharm is also launching a water soluble CBN:THC liquid solution, Northbound Night Cap. Northbound Night Cap utilizes proprietary water-soluble emulsification technology developed in-house by the MediPharm’s Research and Development team. This formulation allows patients and consumers to add CBN to their favourite food or beverage without overpowering taste and liquid separation. Using an in-house emulsification method mitigated the Company’s need to purchase or license formulations like many other cannabis industry beverage brands.
Khiron Life Sciences Corp. (
TSXV: KHRN
) (
OTCQX: KHRNF
), the global medical cannabis leader expanding throughout Latin America and Europe,
has published
in the international peer-reviewed journal
Frontiers in Pain Research
the results of its first clinical study on the use of medical cannabis prescribed to Colombian patients in treating chronic pain. This is the largest study of its kind in Latin America, and the first published clinical evidence on the effectiveness and safety of Khiron’s THC and CBD oil-based cannabis formulations, the two most prescribed products at Khiron’s Zerenia Clinics in Colombia. This is reassuring data for prescribing physicians and health insurance providers on the efficacy, safety, and cost-effectiveness of the Khiron’s products to treat chronic pain. Frontiers journals rank among the most influential in their academic fields based on total citations and ranks as the 3rd most-cited publisher among the 20 largest publishers.
The study, a joint effort by medical researchers from Khiron Life Sciences and doctors from Zerenia Clinics in Colombia and Europe, captures patient-reported outcome measures (“PROMS”) and adverse effects in a large cohort of 2112 adult patients diagnosed with chronic pain of diverse etiology. Between May and September 2021, patients received adjuvant treatment with Khiron’s oral oil-based cannabis formulations at the Latin American Institute of Neurology and Nervous System (ILANS-Zerenia) in Bogotá, Colombia.
“This study, based on Khiron’s medical products, is critical to reassure physicians and health insurance providers of the efficacy of medicinal cannabis to treat chronic pain. The global impact and economic burden of chronic pain in our society, mounting medical evidence will increase access to cannabinoid-based medicines worldwide.” says Alvaro Torres, Khiron CEO and Director. “The recent vote in the US House of Representatives promoting medical research on cannabis clearly shows the pressing need to develop effective and safe cannabis-based medication for suffering patients worldwide. With this and upcoming studies, Khiron will continue to stand above in the field of medical research and to expand the access for patients in those jurisdictions in which we are present”.
Guillermo Moreno-Sanz, the first author of the study and Global Scientific Director of Khiron Life Sciences adds, “We believe these findings to be generalizable across patient populations, considering that our results are extremely well-aligned with those reported by researchers working with similar clinical populations in nations with long-standing medicinal cannabis access programs, such as Israel and Canada.”
This study is groundbreaking for Khiron as most observational and experimental studies investigating the efficacy of medical cannabis for pain management are of relatively short duration and use a disparity of cannabinoid-based products, routes of administration, and dosing regimens. This study is differentiated as it describes the short-, mid- and long-term efficacy and safety of two monovarietal formulations containing THC and CBD in different ratios (1:1 and 1:25, respectively), and investigates the contribution of patient’s sex, and age. Most participants were female (76.1%) with an average age of 58.7 years old. One third of the participants were elderly (>65 years old).
As Khiron continues to expand its research and business globally through Latin America and Europe, additional studies are expected to continue to demonstrate the Company’s business model, creating a 360-solution for health care providers, insurance companies, and patients to benefit from the prescription and positive health outcomes from medical cannabis.
SPOTLITE360 IOT SOLUTIONS, INC. (
CSE: LITE
) (
OTC: SPLTF
)
announced
that it has executed a master terms agreement dated March 30, 2022, to create a strategic relationship with American Cannabis Consulting (
OTCQB:AMMJ
) (ACC) an arm’s length party to the Company. Denver, Colorado based ACC is a nationally recognized business-to-business cannabis consulting solutions provider and licensed owner operator with a number of significant brands and company relationships. As recently as February 25, 2022, ACC announced a partnership with the Bubba Kush cannabis brand.
Under the terms of the Master Agreement, both companies will work together in joint consulting engagements to leverage their combined strengths. SpotLite360’s recent announcement of acquiring a majority interest in E3 Service Group, combined with SpotLite360’s SaaS based technology and ACC’s deep history of indoor cannabis cultivation knowledge can offer best in-class design, build, total cost of ownership, production and financial returns. SpotLite360’s technology will provide supply chain transparency including the necessary proof of sustainability claims.
James Greenwell, President and CEO of SpotLite360, commented, “Our companies’ have a shared vision to assist our clients’ making data driven decisions – across a sustainable agricultural supply chain. SpotLite360 looks forward to working together with ACC to deliver process efficiency, support regulatory and compliance mandates, improves product quality and provide the consumer with the proof of ESG claims that they are now demanding. Our engineering designs and supply chain platform will drive best in class models for optimal agricultural cultivation.”
Both companies are currently working together on significant customer opportunities in seven (7) different states. Most projects are new construction opportunities with several in advanced discussions. Joint announcements are anticipated throughout the remainder of 2022.
Ellis Smith, founder and CEO of ACC, said, “Investors and operators agree, the future of cultivation is not based on old school mechanical systems, but technology, IOT, automation and data driven analytics. We believe consistent and repeatable high-quality product is a direct result of good design, good engineering, best practices, good systems, good data and good decisions. Together our companies’ will partner with our customers for more than a consulting agreement, or a design or an install but for decades of joint successes.”
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
To hear more Investorideas.com podcasts visit:
https://www.investorideas.com/Audio/
.
About Investorideas.com – News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news, third party stock research , guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns:
Crypto Corner
,
Play by Play
sports and stock news,
Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast
,
Cleantech and Climate Change
,
Exploring Mining
,
Betting on Gaming Stocks Podcast
and the
AI Eye Podcast
.
Disclaimer/Disclosure:
Investorideas.com
is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.
Contact management and IR of each company directly regarding specific questions.
More disclaimer info:
https://www.investorideas.com/About/Disclaimer.asp
Learn more about publishing your news release and our other news services on the Investorideas.com newswire
https://www.investorideas.com/News-Upload/
and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter
Tweets by InvestorIdeas
Follow us on Facebook
https://www.facebook.com/Investorideas
Follow us on YouTube
https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800 665 0411
